|
1
|
Willett CG, Czito BG and Bendell JC:
Radiation therapy in stage II and III rectal cancer. Clin Cancer
Res. 13:6903s–6908s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Improved survival with preoperative
radiotherapy in resectable rectal cancer. Swedish rectal cancer
trial. N Engl J Med. 336:980–987. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kapiteijn E, Marijnen CA, Nagtegaal ID,
Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B,
van Krieken JH, et al: Preoperative radiotherapy combined with
total mesorectal excision for resectable rectal cancer. N Engl J
Med. 345:638–646. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ceelen W, Fierens K, Van Nieuwenhove Y and
Pattyn P: Preoperative chemoradiation versus radiation alone for
stage II and III resectable rectal cancer: A systematic review and
meta-analysis. Int J Cancer. 124:2966–2972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sugihara K, Kobayashi H, Kato T, Mori T,
Mochizuki H, Kameoka S, Shirouzu K and Muto T: Indication and
benefit of pelvic sidewall dissection for rectal cancer. Dis Colon
Rectum. 49:1663–1672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Watanabe T, Itabashi M, Shimada Y, et al:
Japanese Society for Cancer of the Colon and Rectum (JSCCR)
Guideline 2014 for treatment of colorectal cancer. Int J Clin
Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fukunaga Y, Higashino M, Tanimura S,
Takemura M and Fujiwara Y: Laparoscopic rectal surgery for middle
and lower rectal cancer. Surg Endosc. 24:145–151. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fujita S, Yamamoto S, Akasu T and Moriya
Y: Outcome of patients with clinical stage II or III rectal cancer
treated without adjuvant radiotherapy. Int J Colorectal Dis.
23:1073–1079. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kusters M, Beets GL, van de Velde CJ,
Beets-Tan RG, Marijnen CA, Rutten HJ, Putter H and Moriya Y: A
comparison between the treatment of low rectal cancer in Japan and
the Netherlands, focusing on the patterns of local recurrence. Ann
Surg. 249:229–235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gérard JP, Conroy T, Bonnetain F, Bouché
O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E,
Maurel J, et al: Preoperative radiotherapy with or without
concurrent fluorouracil and leucovorin in T3-4 rectal cancers:
Results of FFCD 9203. J Clin Oncol. 24:4620–4625. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bosset JF, Calais G, Mineur L, Maingon P,
Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A and
Collette L: Enhanced tumorocidal effect of chemotherapy with
preoperative radiotherapy for rectal cancer: Preliminary
results-EORTC 22921. J Clin Oncol. 23:5620–5627. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gérard JP, Azria D, Gourgou-Bourgade S,
Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E,
de La Roche G, Bouché O, et al: Comparison of two neoadjuvant
chemoradiotherapy regimens for locally advanced rectal cancer:
Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin
Oncol. 28:1638–1644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chua YJ, Barbachano Y, Cunningham D, Oates
JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC and Chau
I: Neoadjuvant capecitabine and oxaliplatin before
chemoradiotherapy and total mesorectal excision in MRI-defined
poor-risk rectal cancer: A phase 2 trial. Lancet Oncol. 11:241–248.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
DeMario MD and Ratain MJ: Oral
chemotherapy: Rationale and future directions. J Clin Oncol.
16:2557–2567. 1998.PubMed/NCBI
|
|
15
|
Diasio RB: Clinical implications of
dihydropyrimidine dehydrogenase inhibition. Oncology (Williston
Park). 13(7 Suppl 3): S17–S21. 1999.
|
|
16
|
Shirasaka T, Shimamato Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shirao K, Ohtsu A, Takada H, Mitachi Y,
Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H
and Satoh A: Phase II study of oral S-1 for treatment of metastatic
colorectal carcinoma. Cancer. 100:2355–2361. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ohtsu A, Baba H, Sakata Y, Mitachi Y,
Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a
novel oral fluorophyrimidine derivative, in patients with
metastatic colorectal carcinoma. S-1 cooperative colorectal
carcinoma study group. Br J Cancer. 83:141–145. 2000.PubMed/NCBI
|
|
19
|
Nakata E, Fukushima M, Takai Y, Nemoto K,
Ogawa Y, Nomiya T, Nakamura Y, Milas L and Yamada S: S-1, an oral
fluoropyrimidine, enhances radiation response of DLD-1/FU human
colon cancer xenografts resistant to 5-FU. Oncol Rep. 16:465–471.
2006.PubMed/NCBI
|
|
20
|
Inomata M, Akagi T, Nakajima K, Etoh T,
Shiraishi N, Tahara K, Matsumoto T, Kinoshita T, Fujii K, Shiromizu
A, et al: Prospective feasibility study to evaluate
neoadjuvant-synchronous S-1+RT for locally advanced rectal cancer:
A multicenter phase II trial (UMIN ID: 03396). Jpn J Clin Oncol.
43:321–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey, J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–47.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cassidy J, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Randomized phase III study of capecitabine plus
oxaliplatin compared with fluorouracil/folinic acid plus
oxaliplatin as first-line therapy for metastatic colorectal cancer.
J Clin Oncol. 26:2006–2012. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berry G, Smith CL, Macaskill P and Irwig
L: Analytic methods for comparing two dichotomous screening or
diagnostic tests applied to two populations of differing disease
prevalence when individuals negative on both tests are unverified.
Stat Med. 21:853–862. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Green SJ and Dahlberg S: Planned versus
attained design in phase II clinical trials. Stat Med. 11:853–862.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aschele C, Cionini L, Lonardi S, Pinto C,
Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti
P, et al: Primary tumor response to preoperative chemoradiation
with or without oxaliplatin in locally advanced rectal cancer:
Pathologic results of the STAR-01 randomized phase III trial. J
Clin Oncol. 29:2773–2780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gérard JP, Azria D, Gourgou-Bourgade S,
Martel-Lafay I, Hennequin C, Etienne PL, Vendrely V, François E, de
La Roche G, Bouché O, et al: Clinical outcome of the ACCORD 12/0405
PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol.
30:4558–4565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rödel C, Liersch T, Becker H, Fietkau R,
Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M,
Raab HR, et al: Preoperative chemoradiotherapy and postoperative
chemotherapy with fluorouracil and oxaliplatin versus fluorouracil
alone in locally advanced rectal cancer: Initial results of the
German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol.
13:679–687. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sadahiro S, Suzuki T, Tanaka A, Okada K,
Kamijo A, Murayama C, Akiba T and Nakayama Y: Phase I/II study of
preoperative concurrent chemoradiotherapy with S-1 for locally
advanced, resectable rectal adenocarcinoma. Oncology. 81:306–311.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kuremsky JG, Tepper JE and McLeod HL:
Biomarkers for response to neoadjuvant chemoradiation for rectal
cancer. Int J Radiat Oncol Biol Phys. 74:673–688. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miura K, Fujibuchi W, Ishida K, Naitoh T,
Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C and
Sasaki I: Inhibitor of apoptosis protein family as diagnostic
markers and therapeutic targets of colorectal cancer. Surg Today.
41:175–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luna-Perez P, Arriola EL, Cuadra Y,
Alvarado I and Quintero A: p53 protein overexpression and response
to induction chemoradiation therapy in patients with locally
advanced rectal adenocarcinoma. Ann Surg Oncol. 5:203–208. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Spitz FR, Giacco GG, Hess K, Larry L, Rich
TA, Janjan N, Cleary KR and Skibber JM: p53 immunohistochemical
staining predicts residual disease after chemoradiation in patients
with high-risk rectal cancer. Clin Cancer Res. 3:1685–1690.
1997.PubMed/NCBI
|
|
33
|
Esposito G, Pucciarelli S, Alaggio R,
Giacomelli L, Marchiori E, Iaderosa GA, Friso ML, Toppan P,
Chieco-Bianchi L and Lise M: P27kip1 expression is associated with
tumor response to preoperative chemoradiotherapy in rectal cancer.
Ann Surg Oncol. 8:311–318. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin LC, Lee HH, Hwang WS, Li CF, Huang CT,
Que J, Lin KL, Lin FC and Lu CL: p53 and p27 as predictors of
clinical outcome for rectal-cancer patients receiving neoadjuvant
therapy. Surg Oncol. 15:211–216. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Spindler KL, Nielsen JN, Lindebjerg J and
Jakobsen A: Germline polymorphisms may act as predictors of
response to preoperative chemoradiation in locally advanced T3
rectal tumors. Dis Colon Rectum. 50:1363–1369. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Giralt J, de las Heras M, Cerezo L, Eraso
A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Majó J, et
al: The expression of epidermal growth factor receptor results in a
worse prognosis for patients with rectal cancer treated with
preoperative radiotherapy: A multicenter, retrospective analysis.
Radiother Oncol. 74:101–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim JS, Kim JM, Li S, Yoon WH, Song KS,
Kim KH, Yeo SG, Nam JS and Cho MJ: Epidermal growth factor receptor
as a predictor of tumor downstaging in locally advanced rectal
cancer patients treated with preoperative chemoradiotherapy. Int J
Radiat Oncol Biol Phys. 66:195–200. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jakob C, Liersch T, Meyer W, Becker H,
Baretton GB and Aust DE: Predictive value of Ki67 and p53 in
locally advanced rectal cancer: Correlation with thymidylate
synthase and histopathological tumor regression after neoadjuvant
5-FU-based chemoradiotherapy. World J Gastroenterol. 14:1060–1066.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim NK, Park JK, Lee KY, Yang WI, Yun SH,
Sung J and Min JS: p53, BCL-2 and Ki-67 expression according to
tumor response after concurrent chemoradiotherapy for advanced
rectal cancer. Ann Surg Oncol. 8:418–424. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kudrimoti M, Lee EY, Kang Y, Ahmed M and
Mohiuddin M: Genetic markers predictive of response to induction
chemoradiotherapy for locally advanced rectal cancers. J Ky Med
Assoc. 105:18–22. 2007.PubMed/NCBI
|
|
41
|
Chang HJ, Jung KH, Kim DY, Jeong SY, Choi
HS, Kim YH, Sohn DK, Yoo BC, et al: B, a predictive marker for
therapeutic response to preoperative chemoradiotherapy in patients
with rectal carcinoma. Hum Pathol. 36:364–371. 2005. View Article : Google Scholar : PubMed/NCBI
|
